Arvinas, Inc. (ARVN)
ARVN Chart as of 2025-03-11
Stock Information
| CEO: | – |
| CFO: | – |
| Employees: | 430 |
| Address: | 5 Science Park, New Haven, CT, United States |
| Country: | United States |
| Website: | https://www.arvinas.com |
| Listing Date: | – |
| Founded: | – |
| Founder: | – |
| Current Price: | 8.300000190734863 USD |
| Today Change: | -21.55% |
| Outstanding Shares: | 68,771,904 |
| Volume: | 18,980,784 |
| Avg Volume: | 1,117,512 |
| Expert Target Price: | 58.5500 (Institutions: 0) |
| EPS: | – |
| PER: | – |
| Dividend Date: | – |
| Last Split Date: | – |
| Last Split Factor: | – |
Key Executives
| Name | Title | Pay | Year |
|---|---|---|---|
| Dr. John G. Houston Ph.D. | Chairperson, CEO & President | 1.14M | — |
| Dr. Ian Taylor Ph.D. | President of Research & Development and Chairman of Scientific Advisory Board | 732.26k | — |
| Mr. Andrew R. Saik | CFO & Treasurer | — | — |
| Mr. David K. Loomis M.B.A. | VP & Chief Accounting Officer | — | — |
| Ms. Angela M. Cacace Ph.D. | Chief Scientific Officer | — | — |
| Mr. Jared M. Freedberg J.D. | General Counsel & Corporate Secretary | — | — |
| Mr. Steve Weiss | Senior VP & Chief Human Resources Officer | — | — |
| Dr. Randy Teel Ph.D. | Chief Business Officer | — | — |
| Ms. Lisa Sinclair | Senior Vice President of Corporate Operations | — | — |
| Mr. Paul McInulty | Senior Vice President of Regulatory Affairs | — | — |
Financials
Income Statement
| Metric | Amount |
|---|---|
| Total Revenue | 263,400,000 |
| Cost Of Revenue | – |
| Gross Profit | – |
| Operating Income | -250,200,000 |
| Net Income | -198,900,000 |
Balance Sheet
| Metric | Amount |
|---|---|
| Total Assets | 1,091,400,000 |
| Total Liabilities | – |
| Total Stockholder Equity | – |
Cash Flow
| Metric | Amount |
|---|---|
| Total Cash From Operating Activities | – |
| Capital Expenditures | – |
SEC Filings (Gemini Summaries)
| AccNo | Date | Summary |
|---|---|---|
| 0001655759-25-000057 | 2025-03-11 | Arvinas (ARVN) filed an 8-K on 2025-03-11. A Phase 3 trial (VERITAC-2) of vepdegestrant for ER+/HER2- breast cancer met its primary endpoint for ESR1m population showing improved progression-free survival vs fulvestrant. Will continue to assess overall survival. |
| 0001655759-25-000054 | 2025-02-25 | Form 4 filing by David K Loomis, Chief Accounting Officer of ARVINAS, INC. (ARVN), reports a transaction on 02/24/2025. 1,214 shares of common stock were disposed of at $16.75 per share. |
| 0001655759-25-000052 | 2025-02-25 | SEC Form 4 filing by Angela Cacace, Chief Scientific Officer of Arvinas, Inc. (ARVN), regarding changes in beneficial ownership of common stock on 02/24/2025. 3,061 shares were disposed of at $16.75. |
| 0001655759-25-000050 | 2025-02-25 | Form 4 filing by Ian Taylor, President of RD at Arvinas, Inc. (ARVN) on 02/24/2025. Reports disposition of 7,356 shares of common stock at $16.75, leaving 160,785 shares beneficially owned. |
| 0001655759-25-000048 | 2025-02-25 | SEC Form 4 filing by John G Houston, President and CEO of Arvinas, Inc. (ARVN), regarding changes in beneficial ownership of common stock on 02/24/2025. Sale of 26,184 shares at $16.75. |
News Summary
– Arvinas’ (ARVN) Buy Rating Reiterated at Guggenheim
2025-02-15 09:04:39 | ETF Daily News
Guggenheim reissued their buy rating on shares of Arvinas (NASDAQ:ARVN – Free Report) in a report released on Wednesday morning,Benzinga reports. They currently have a $57.00 target price on the stock. Several other research analysts have also recently weighe…
Link
– Arvinas’ (ARVN) “Overweight” Rating Reaffirmed at Cantor Fitzgerald
2025-02-10 17:15:20 | ETF Daily News
Cantor Fitzgerald restated their overweight rating on shares of Arvinas (NASDAQ:ARVN – Free Report) in a research note published on Friday. HC Wainwright reiterated a “buy” rat…
Link
– Arvinas’ (ARVN) Outperform Rating Reaffirmed at BMO Capital Markets
2025-02-14 08:01:01 | ETF Daily News
Arvinas (NASDAQ:ARVN – Get Free Report)‘s stock had its “outperform” rating reiterated by BMO Capital Markets in a research report issued to clients and investors on Wednesday. They currently have a $82.00 target price on the stock.
Link
– Citigroup Cuts Arvinas (NASDAQ:ARVN) Price Target to $19.00
2025-03-10 05:33:36 | ETF Daily News
Arvinas (NASDAQ:ARVN – Free Report) had its price objective trimmed by Citigroup from $28.00 to $19.00 in a research report released on Friday morning. The brokerage currently has a neutral rating on the stock.
Link
– Arvinas (NASDAQ:ARVN) Price Target Raised to $45.00
2025-02-15 08:22:56 | ETF Daily News
Arvinas (NASDAQ:ARVN – Free Report) had its price target hoisted by Oppenheimer from $40.00 to $45.00 in a report published on Wednesday,Benzinga reports. They currently have an outperform rating on the stock. Several other brokerages also recently weighed in…
Link
Analysis of Today’s Move
Arvinas (ARVN) stock likely fell today due to a confluence of factors. While some analysts maintained positive ratings, the Citigroup price target cut significantly impacted investor sentiment. This downgrade, from $28 to $19 with a neutral rating, signals decreased confidence. The news directly contradicts earlier optimistic reports. This creates uncertainty about the stock’s short-term potential.
Despite positive Phase 3 trial results announced in an 8-K filing, investor anxieties increased. The trial met its primary endpoint regarding progression-free survival. However, the market might be concerned about the overall survival data. This metric is still being assessed and could impact the long-term value of vepdegestrant. The initial enthusiasm quickly faded upon further scrutiny.
Form 4 filings showing insider selling activity near the end of February exacerbated the negative trend. Multiple executives, including the CEO and CSO, disposed of shares. These sales, executed at $16.75 per share, could raise concerns. It might indicate that insiders believe the stock is currently overvalued. This perceived lack of confidence from company leadership is concerning.
The combination of a lowered price target and insider selling likely outweighed positive analyst ratings. The trial results, while positive, were not enough to offset the negative signals. The market reacted negatively, leading to a stock price decline. Investors need to consider both positive and negative indicators. Therefore, a comprehensive view is essential before making investment decisions.
This stock has shown a change of -21.55% today.
Please consider that all investment decisions carry risk;
none of the content here should be construed as financial advice.
Always do your own research or consult a professional before making investment decisions.
The information provided in this article is for informational purposes only
and does not constitute legal, tax, or investment advice.
Investing involves risk, including the potential loss of principal.
Leave a Reply